Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its ... The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...

Corbus Pharmaceuticals Holdings Inc. closed 89.03% below its 52-week high of $61.90, which the company reached on July 31st.

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors ... The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the ...